Seattle Genetics, Inc. (SGEN) Position Raised by University of Notre Dame DU Lac

University of Notre Dame DU Lac boosted its position in Seattle Genetics, Inc. (NASDAQ:SGEN) by 40.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,319 shares of the biotechnology company’s stock after purchasing an additional 16,024 shares during the period. University of Notre Dame DU Lac’s holdings in Seattle Genetics were worth $3,010,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Aperio Group LLC increased its holdings in Seattle Genetics by 0.3% in the second quarter. Aperio Group LLC now owns 31,693 shares of the biotechnology company’s stock valued at $1,640,000 after buying an additional 91 shares in the last quarter. US Bancorp DE increased its holdings in Seattle Genetics by 53.2% in the second quarter. US Bancorp DE now owns 10,943 shares of the biotechnology company’s stock valued at $567,000 after buying an additional 3,798 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in Seattle Genetics by 4.2% in the second quarter. Great West Life Assurance Co. Can now owns 43,539 shares of the biotechnology company’s stock valued at $2,250,000 after buying an additional 1,762 shares in the last quarter. First Manhattan Co. increased its holdings in Seattle Genetics by 31.3% in the second quarter. First Manhattan Co. now owns 3,150 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 750 shares in the last quarter. Finally, Pictet Asset Management Ltd. increased its holdings in Seattle Genetics by 48.4% in the second quarter. Pictet Asset Management Ltd. now owns 706,316 shares of the biotechnology company’s stock valued at $45,190,000 after buying an additional 230,492 shares in the last quarter. Hedge funds and other institutional investors own 98.96% of the company’s stock.

A number of research analysts have issued reports on the stock. Oppenheimer assumed coverage on shares of Seattle Genetics in a report on Tuesday, October 10th. They issued a “hold” rating for the company. Cantor Fitzgerald set a $46.00 price objective on shares of Seattle Genetics and gave the stock a “hold” rating in a research note on Tuesday, October 10th. Cann began coverage on shares of Seattle Genetics in a research note on Wednesday, November 8th. They set a “hold” rating for the company. Bank of America raised shares of Seattle Genetics from an “underperform” rating to a “neutral” rating in a research note on Friday, October 27th. Finally, J P Morgan Chase & Co raised their price objective on shares of Seattle Genetics from $55.00 to $60.00 and gave the stock a “neutral” rating in a research note on Monday, October 30th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $63.53.

In related news, insider Clay B. Siegall sold 18,832 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $53.49, for a total transaction of $1,007,323.68. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Vaughn B. Himes sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $59.97, for a total transaction of $599,700.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 163,481 shares of company stock worth $9,550,402. 34.70% of the stock is owned by company insiders.

Shares of Seattle Genetics, Inc. (NASDAQ SGEN) opened at $56.05 on Wednesday. Seattle Genetics, Inc. has a 1 year low of $45.31 and a 1 year high of $71.32.

Seattle Genetics (NASDAQ:SGEN) last announced its earnings results on Thursday, October 26th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.23. Seattle Genetics had a negative net margin of 26.53% and a negative return on equity of 32.41%. The firm had revenue of $135.29 million for the quarter, compared to analyst estimates of $112.76 million. During the same quarter last year, the business earned ($0.23) earnings per share. Seattle Genetics’s revenue was up 27.3% compared to the same quarter last year. equities research analysts predict that Seattle Genetics, Inc. will post -0.93 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://stocknewstimes.com/2017/12/06/seattle-genetics-inc-sgen-position-raised-by-university-of-notre-dame-du-lac.html.

About Seattle Genetics

Seattle Genetics, Inc is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC).

Institutional Ownership by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply